Weight-Loss Drugs In India: Who Sells What And At What Price? Check Full List

Last Updated:March 23, 2026, 12:48 IST

New drugs like semaglutide work by suppressing appetite and improving metabolism, delivering significant weight loss without surgery

From doctor consultations to advertisements on TV, anti-obesity drugs are the latest hot topic in India. The country is witnessing a sharp surge in demand for the drugs, led by a new class of medicines known as GLP-1 receptor agonists. Once niche treatments for diabetes, these drugs, such as the well-known Wegovy and Ozempic, are now reshaping the country’s pharmaceutical landscape.

The clamour for weight-loss drugs is both a medical need and a technological breakthrough.

India is seeing a steady rise in obesity and lifestyle diseases, making weight-loss treatments a major healthcare priority. New drugs like semaglutide work by suppressing appetite and improving metabolism, delivering significant weight loss without surgery. Globally, these drugs are among the fastest-growing pharma segments, with the market expected to cross $30 billion. In India, this demand is now translating into rapid adoption.

ALSO READ | Mounjaro Vs Wegovy In The Great Weight-Loss Drug Battle. Who Has The Edge In India?

As per several market watchers, India’s anti-obesity drug market is still small but expanding quickly. The estimated size in 2025 was Rs 1,000–Rs 1,200 crore and the number is expected to grow to Rs 4,500–Rs 5,000 crore by 2030. Some projections suggest even steeper expansion as affordability improves.

The growth is being driven by urban lifestyle changes, increasing diagnosis of obesity as a disease, and rising awareness of pharmacological weight loss.

The biggest trigger has been the expiry of semaglutide’s patent in India in March 2026.

This led to a flood of low-cost generic versions from Indian pharma companies, which led to prices dropping sharply—from Rs 8,000-Rs 16,000/month (innovator brands) to much lower levels. It also opened up the doors for multiple players like Sun Pharma, Zydus, Natco, Alkem, and others. Within hours of the patent expiry, several companies launched competing products, marking what industry experts call India’s “GLP-1 moment", Forbes reported.

Indian companies are rushing in because this is one of the most lucrative new pharma segments globally, mainly because of the high and growing demand for weight loss, the long-term treatment cycles (patients stay on therapy for months or years), and opportunity to undercut global giants like Novo Nordisk.

ALSO READ | Weight-Loss Injections Explained: How Semaglutide and Tirzepatide Are Changing Obesity Treatment

Indian firms are leveraging lower manufacturing costs, domestic distribution networks, and price-sensitive market positioning, which has triggered a price war that is rapidly expanding access.

Here are the popular anti-obesity drugs available in the market with their price comparisons:

Despite the boom, there are important caveats that doctors warn users of. Most importantly, these drugs require medical supervision. Their side effects include nausea and gastrointestinal issues and weight regain is common after stopping treatment. Apart from this, long-term affordability remains a concern. In short, these are not “magic pills" but transformational tools when used correctly.

(With inputs from Himani Chandna in New Delhi)

News india Weight-Loss Drugs In India: Who Sells What And At What Price? Check Full List

Read More